Highlights Nanexa AB

Equities

NANEXA

SE0007074166

Market Closed - Nasdaq Stockholm Other stock markets 11:29:50 2024-04-26 am EDT			5-day change	1st Jan Change
0.606 ^SEK	-5.31%		-8.46%	-50.73%

Apr. 16	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI
Mar. 08	Transcript : Nanexa AB - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	Apr. 16	CI
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	Dec. 20	CI
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	Nov. 29	MT
Nanexa AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Nanexa AB Completes Clinical Phase I Study with NEX-20	23-10-05	CI
Nanexa AB Receives Patent in India	23-08-30	CI
Nanexa AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22	23-08-22	CI
Nanexa AB Obtains Pharmacokinetic Data from the NEX-20 Phase 1 Study Confirming Controlled Release of Lenalidomide	23-08-22	CI
Nanexa AB Completes Planned Recruitment to the Phase 1 Study of NEX-20	23-06-09	CI
Nanexa AB Signs Contract with Leading International Diabetes Cro for Phase I Study with Nex-22	23-06-01	CI
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Nanexa AB Announces Positive Outcome in the First Preclinical Study with NEX-22	23-03-23	CI
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-16	CI
Nanexa Starts the Phase 1 Study of NEX-20 According to Plan	22-12-06	CI
Nanexa, VitriVax Settle Patent Infringement Case Over Drug Delivery System	22-11-16	MT
Nanexa Receives Approval to Start Clinical Trial with NEX-20	22-11-14	CI
Nanexa AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-25	CI
Nanexa Signs Deal to Evaluate PharmaShell's Potential Use in Intravitreal Drug Delivery	22-10-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nanexa AB

Equities

NANEXA

SE0007074166

Highlights

Filters